A detailed history of Palo Alto Investors LP transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Palo Alto Investors LP holds 732,400 shares of RLMD stock, worth $2.09 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares
732,400
Previous 732,400 -0.0%
Holding current value
$2.09 Million
Previous $2.2 Million 7.97%
% of portfolio
0.33%
Previous 0.28%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$2.22 - $3.54 $422,466 - $673,662
190,300 Added 35.1%
732,400 $1.8 Million
Q1 2023

May 15, 2023

BUY
$2.24 - $4.76 $1.21 Million - $2.58 Million
542,100 New
542,100 $1.23 Million

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $81.5M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Palo Alto Investors LP Portfolio

Follow Palo Alto Investors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Palo Alto Investors LP with notifications on news.